Foresite Capital LYEL Position
ActiveForesite Capital held their position in Lyell Immunopharma Inc. (LYEL) in Q4 2025, holding $24.6M worth of shares across 800,399 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds LYEL.
About Lyell Immunopharma Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
4.8%
9.5 days to cover
Foresite Capital LYEL Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 800,399 | — | $24.6M |
| Q3 2025 | Held | 800,399 | — | $13.0M |
| Q2 2025 | Decreased | 800,399 | -15,207,600 | $7.1M |
| Q1 2025 | Increased | 16,007,999 | +7,682,999 | $8.6M |
| Q4 2024 | Held | 8,325,000 | — | $5.3B |
| Q3 2024 | Held | 8,325,000 | — | $11.5M |
| Q2 2024 | Held | 8,325,000 | — | $12.1M |
| Q1 2024 | Held | 8,325,000 | — | $18.6M |
| Q4 2023 | Decreased | 8,325,000 | -459,813 | $16.2M |
| Q3 2023 | Decreased | 8,784,813 | -915,187 | $12.9M |
| Q2 2023 | Decreased | 9,700,000 | -300,000 | $30.8M |
| Q1 2023 | New | 10,000,000 | +10,000,000 | $23.6M |
Frequently Asked Questions
Does Foresite Capital own LYEL?
Yes. As of Q4 2025, Foresite Capital holds 800,399 shares of Lyell Immunopharma Inc. (LYEL) valued at $24.6M. This data comes from their SEC 13F filing.
How many hedge funds own LYEL?
2 specialist biotech hedge funds currently hold LYEL, including OrbiMed Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Foresite Capital first buy LYEL?
Foresite Capital's position in LYEL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Foresite Capital's LYEL position increasing or decreasing?
Foresite Capital held their LYEL position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LYELCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Foresite CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →